MucoLife Therapeutics CEO to Present at Inaugural COPD Drug Development Summit in Boston
Gothenburg, Sweden — [June 29, 2026] — MucoLife Therapeutics AB, a preclinical biopharmaceutical company developing first-in-class therapies for muco-obstructive lung diseases, today announced that CEO Thaher Pelaseyed will present at the inaugural COPD Drug Development Summit, to be held 15–17 September 2026 in Boston, MA, alongside respiratory leaders from AstraZeneca, Merck, Sanofi, and Johnson & Johnson.
The summit is the first industry-led forum dedicated to uniting discovery, preclinical, translational, clinical, and regulatory expertise to accelerate novel therapies for COPD, one of the world's largest areas of unmet medical need. MucoLife Therapeutics will participate across two sessions.
Talk — Wednesday, 16 September 2026, 15:45
"Targeting Muco-Obstructive Lesions to Redefine COPD Treatment"
Thaher Pelaseyed will present on MLT-001, the company’s lead asset and a first-in-class inhaled mucus modulator, as a novel approach to reverse airway obstruction in COPD. The talk will address three key points:
Mucus plugs persist as a critical and unaddressed driver of COPD morbidity and mortality, remaining present even in patients escalated to triple therapy or biological agents.
MLT-001 directly dissolves airway mucus plugs through a novel mechanism of action, chelating the calcium ions that stabilize the MUC5B and MUC5AC mucins forming the mucus plug matrix.
Preclinical efficacy of 90% mucus plug resolution has been demonstrated across multiple preclinical models, at a daily dose below 2.5 mg and with a therapeutic index exceeding 1,000×.
The presentation will define the addressable COPD patient subgroup with high mucus burden, outline MLT-001's positioning as a once-daily inhaled add-on maintenance therapy within the existing treatment paradigm, and explore the broader platform potential of the mechanism across non-CF bronchiectasis and asthma.
Workshop B — Tuesday, 15 September 2026, 13:00–16:00
"Unlocking the Power of Advanced Imaging Technologies from MRI to MicroCT & Evolving AI & ML to Drug Development from POC to Target Engagement, Diagnosis & Disease Progression in COPD"
Pelaseyed will co-lead this hands-on pre-conference workshop alongside a clinical imaging investigator from Brigham and Women's Hospital, Harvard Medical School. The session will explore how advanced imaging modalities and machine learning approaches are being used to track COPD disease progression, identify patient subtypes, and accelerate early proof-of-concept and translational decision-making.
About Mucus Plugging in COPD
Airway mucus plugging affects an estimated 50% of moderate-to-severe COPD patients and is independently associated with disease progression, exacerbation risk, and increased mortality. Despite its clinical significance, no approved therapy directly targets the biochemical composition of airway mucus plugs. Advances in CT imaging now enable reliable quantification of mucus plug burden, establishing mucus plug score as an emerging and validated endpoint for interventional trials.
About MLT-001
MLT-001 is a first-in-class inhaled mucus modulator originating from the Mucin Biology Group of Prof. Gunnar C. Hansson at the University of Gothenburg, Sweden. MucoLife is advancing MLT-001 toward IND-enabling studies and Phase 1 entry targeted for 2027.
About MucoLife Therapeutics AB
MucoLife Therapeutics AB is a preclinical biopharmaceutical company developing MLT-001 for COPD, cystic fibrosis, non-CF bronchiectasis, and asthma. MucoLife Therapeutics is headquartered in Gothenburg, Sweden.
Summit details: www.copd-drug-development.com
Press contact MucoLife Therapeutics:
Thaher Pelaseyed, CEO
MucoLife Therapeutics AB
tpelaseyed@mucolife.com
www.mucolife.com
This press release contains forward-looking statements based on current expectations and assumptions. Actual results may differ materially. Preclinical results do not guarantee clinical outcomes.